ArticleCancers2022

T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer.

Thibaut Sanglier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.